SENESCENCE THERAPY
"""PRO –SENESCENCE” THERAPY IN PEDIATRIC BRAIN TUMORS"
| Coordinatore | Ente Ospedaliero Cantonale
Organization address
address: Vialle Officina 3 contact info |
| Nazionalità Coordinatore | Switzerland [CH] |
| Totale costo | 100˙000 € |
| EC contributo | 100˙000 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-2007-4-3-IRG |
| Funding Scheme | MC-IRG |
| Anno di inizio | 2009 |
| Periodo (anno-mese-giorno) | 2009-02-23 - 2013-02-22 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
Ente Ospedaliero Cantonale
Organization address
address: Vialle Officina 3 contact info |
CH (Bellinzona) | coordinator | 100˙000.00 |
| 2 |
"PROVINCIA RELIGIOSA DI SAN PIETRO DELL'ORDINE OSPEDALIERO DI SAN GIOVANNI DI DIO, DETTO FATEBENEFRATELLI"
Organization address
address: Via Cassia 600 contact info |
IT (ROMA) | participant | 100˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The irreversible cell growth arrest, termed cellular senescence, is emerging as an intrinsic tumour suppressive mechanism, which restricts progression of early cancerous lesions in humans. We have recently reported, a new type of cellular senescence, which occurs after the acute inactivation of the tumour suppressor Pten and significantly opposes tumorigenesis in vivo. Pten induced cellular senescence (PICS) occurs at early time points after Pten inactivation even in absence of cellular proliferation and DNA Damage. I will discuss the mechanism that trigger PICS in cancer, hailing the potential therapeutic implication of p53 stabilizing drugs and Pten inhibitors. Importantly, I will discuss how the oncogenic stress induced by complete loss of Pten can still triggers senescence in cells with low proliferative potential, such as cancer stem cells. I propose to apply this model to the treatment of pediatric brain tumors.'